The Business of Biofabrication

In one of France’s largest medtech deals of the year, Lattice Medical has secured €43 million in Series B funding to accelerate the clinical and industrial development of its MATTISSE implant — a 3D-printed, fully resorbable scaffold designed for natural breast tissue regeneration after cancer.

The round was led by the SPI Fund, managed by Bpifrance on behalf of the French government under the France 2030 investment plan, with participation from Blast.Club, Sprim Global Investments, TIDJEE, and returning investors including the EIC Fund, Captech Santé, Nord France Amorçage, and FIRA Nord Est. Legal advisors McDermott Will & Emery and Avolta supported the transaction.

Reindustrializing Healthcare Through France 2030

Created to strengthen national industrial capacity and sovereignty, the SPI Fund (“Sociétés de Projets Industriels”) invests in projects that combine deep technological innovation with economic impact and sustainability. Operated by Bpifrance, it serves as one of the key levers of France 2030—a €54 billion initiative aimed at positioning France as a global leader in health, energy, and deep-tech manufacturing.

In a statement, Magalie Clément, Director of the SPI Fund at Bpifrance, highlighted that:

“Beyond the technological breakthrough of MATTISSE and RODIN, Lattice Medical offers an innovative, autologous alternative for soft-tissue reconstruction—a true public health priority. This project perfectly embodies the France 2030 mission: combining innovation, patient well-being, and industrial revitalization.”

By supporting Lattice Medical, the SPI Fund is reinforcing a regional biomanufacturing hub in Lille, creating high-skilled jobs while anchoring advanced 3D printing and bioresorbable materials production within France’s borders.

Expanding a Clinical and Industrial Platform

The new capital will allow Lattice Medical to:

• Advance clinical trials for its MATTISSE and RODIN implants toward European market approval;
• Build an industrial-scale cleanroom manufacturing site capable of producing resorbable implants and contract manufacturing via Lattice Services;
• Extend its platform technology to new soft-tissue indications, beyond breast reconstruction.

CEO Julien Payen called the investment “a turning point for Lattice Medical,” emphasizing the company’s dual focus on scientific excellence and industrial re-localization.

“We’re reinventing tissue reconstruction after cancer while building a next-generation medtech company that contributes directly to the health, industry, and future of France.”

---

From Lab to Life: The MATTISSE and RODIN Systems

Lattice Medical’s flagship device, MATTISSE, is a biodegradable, patient-specific breast implant that leverages 3D printing and resorbable biomaterials to support the regeneration of natural adipose tissue.
Unlike silicone or permanent synthetic implants, MATTISSE fully resorbs over time, leaving only the patient’s own tissue—an approach that may dramatically reduce long-term complications and improve psychological recovery after mastectomy.

Its second device, RODIN, extends the same core technology to repair large soft-tissue defects, potentially addressing reconstructive needs in trauma and oncology surgery.

About Lattice Medical

Founded in 2017 in Lille, Lattice Medical grew out of a collaboration between surgeons, textile engineers, and materials scientists aiming to merge tissue engineering principles with scalable biomanufacturing.

The company has since developed a proprietary workflow combining biopolymer 3D printing, clean-room manufacturing, and localized supply chains, allowing complete control of production from prototype to implant.

With operations in Wervicq-Sud, Lattice Medical exemplifies a new generation of European medtech startups that are bridging the gap between bioprinting research and industrial implementation. Its mission is simple yet transformative: to make regenerative reconstruction accessible, natural, and free of permanent foreign materials.

Read more here.